Urogen Pharma (NASDAQ:URGN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Urogen Pharma (NASDAQ:URGN) has earned an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $52.3750.

URGN has been the subject of a number of recent research reports. The Goldman Sachs Group reissued a “neutral” rating and set a $44.00 price objective on shares of Urogen Pharma in a research note on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research note on Friday, July 17th. UBS Group reiterated a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. Oppenheimer raised their price target on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $56.00 price target on shares of Urogen Pharma in a report on Thursday, September 10th.

Insider Buying and Selling

In other Urogen Pharma news, insider Mark Schoenberg sold 871 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $42.92, for a total transaction of $37,383.32. Following the completion of the sale, the insider directly owned 59,882 shares in the company, valued at $2,570,135.44. This represents a 1.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel Jason Smith sold 1,519 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total transaction of $64,618.26. Following the completion of the sale, the general counsel directly owned 53,141 shares of the company’s stock, valued at $2,260,618.14. The trade was a 2.78% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 73,067 shares of company stock worth $3,356,854. 4.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Urogen Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of URGN. Opaleye Management Inc. lifted its holdings in Urogen Pharma by 0.7% in the 2nd quarter. Opaleye Management Inc. now owns 1,439,996 shares of the company’s stock worth $52,992,000 after buying an additional 9,996 shares in the last quarter. Engineers Gate Manager LP acquired a new stake in shares of Urogen Pharma during the second quarter valued at about $603,000. Squarepoint Ops LLC acquired a new stake in shares of Urogen Pharma during the second quarter valued at about $431,000. Wellington Management Group LLP increased its position in shares of Urogen Pharma by 15.1% during the second quarter. Wellington Management Group LLP now owns 115,362 shares of the company’s stock worth $4,245,000 after acquiring an additional 15,147 shares during the last quarter. Finally, Palo Alto Investors LP purchased a new stake in shares of Urogen Pharma during the second quarter worth about $901,600. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Urogen Pharma Stock Down 0.1%

Shares of Urogen Pharma stock opened at $43.20 on Thursday. Urogen Pharma has a 52-week low of $15.86 and a 52-week high of $50.81. The company’s 50-day simple moving average is $43.86 and its 200-day simple moving average is $32.57. The firm has a market cap of $2.11 billion, a price-to-earnings ratio of -21.82 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The company had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million. Equities research analysts anticipate that Urogen Pharma will post -0.2 EPS for the current year.

About Urogen Pharma

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company uses its proprietary RTGel reverse-thermal hydrogel technology to provide sustained delivery of medicines directly to affected tissues.

UroGen’s primary commercial product is JELMYTO (mitomycin), a gel-based formulation approved in the United States for the treatment of adults with low-grade upper tract urothelial cancer. The company’s pipeline has also included UGN-102, an investigational formulation of mitomycin being developed for patients with low-grade, intermediate-risk non-muscle-invasive bladder cancer.

Founded in 2004, UroGen is headquartered in Princeton, New Jersey, and primarily serves the U.S.